[{"to": "426", "prefix": " additive effect may be observed when co-administered with ", "from": "421", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "558", "prefix": " inducers: It may be necessary to increase the dose of ", "from": "553", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "752", "prefix": "trong inducer, it may be necessary to decrease the dose of ", "from": "747", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "865", "prefix": "inistration of divalproex sodium increased Cmax and AUC of ", "from": "854", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " by approximately 50%. Adjust dose of INVEGA "}, {"to": "909", "prefix": "d AUC of paliperidone by approximately 50%. Adjust dose of ", "from": "904", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "1166", "prefix": "Potential for ", "from": "1161", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "1281", "prefix": " \n                        Given the primary CNS effects of ", "from": "1270", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " [see Adverse Reactions "}, {"to": "1324", "prefix": "], ", "from": "1319", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "1428", "prefix": "combination with other centrally acting drugs and alcohol. ", "from": "1417", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " may antagonize the effect of levodopa and other dopamine ag"}, {"to": "1629", "prefix": "tatic hypotension, an additive effect may be observed when ", "from": "1624", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "1776", "prefix": "].\n                        ", "from": "1765", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is not expected to cause clinically important pharmacokinet"}, {"to": "1980", "prefix": "es. In vitro studies in human liver microsomes showed that ", "from": "1969", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " does not substantially inhibit the metabolism of drugs meta"}, {"to": "2175", "prefix": "10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Therefore, ", "from": "2164", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is not expected to inhibit clearance of drugs that are meta"}, {"to": "2316", "prefix": " these metabolic pathways in a clinically relevant manner. ", "from": "2305", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is also not expected to have enzyme inducing properties.\n  "}, {"to": "2410", "prefix": "o have enzyme inducing properties.\n                        ", "from": "2399", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is a weak inhibitor of P-glycoprotein "}, {"to": "2627", "prefix": "           Pharmacokinetic interaction between lithium and ", "from": "2622", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "2722", "prefix": "         In a drug interaction study, co-administration of ", "from": "2717", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3081", "prefix": "ad comparable valproate average plasma concentrations when ", "from": "3076", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3369", "prefix": "Potential for Other Drugs to Affect ", "from": "3364", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3451", "prefix": "            \n                     \n                        ", "from": "3440", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, "}, {"to": "3689", "prefix": "dicate that CYP2D6 and CYP3A4 may be minimally involved in ", "from": "3678", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " metabolism, in vivo studies do not show decreased eliminati"}, {"to": "3885", "prefix": " of total body clearance. In vitro studies have shown that ", "from": "3874", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is a P-gp substrate.\n                        Co-administrat"}, {"to": "3958", "prefix": "gp substrate.\n                        Co-administration of ", "from": "3953", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "4169", "prefix": "approximately 37% in the mean steady-state Cmax and AUC of ", "from": "4158", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": ". This decrease is caused, to a substantial degree, by a 35%"}, {"to": "4273", "prefix": "ubstantial degree, by a 35% increase in renal clearance of ", "from": "4262", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": ". A minor decrease in the amount of drug excreted unchanged "}, {"to": "4440", "prefix": " little effect on the CYP metabolism or bioavailability of ", "from": "4429", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " during carbamazepine co-administration. On initiation of ca"}, {"to": "4531", "prefix": "dministration. On initiation of carbamazepine, the dose of ", "from": "4526", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "4651", "prefix": "nversely, on discontinuation of carbamazepine, the dose of ", "from": "4646", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "4740", "prefix": "luated and decreased if necessary.\n                        ", "from": "4729", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is metabolized to a limited extent by CYP2D6 [see Clinical "}, {"to": "4903", "prefix": "n study in healthy subjects in which a single 3 mg dose of ", "from": "4898", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "5010", "prefix": ", ", "from": "4999", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " exposures were on average 16% "}, {"to": "5251", "prefix": "                     Co-administration of a single dose of ", "from": "5246", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "5419", "prefix": "in an increase of approximately 50% in the Cmax and AUC of ", "from": "5408", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": ". Dosage reduction for INVEGA "}, {"to": "5448", "prefix": " in the Cmax and AUC of paliperidone. Dosage reduction for ", "from": "5443", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "5482", "prefix": " should be considered when ", "from": "5477", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "5623", "prefix": "           Pharmacokinetic interaction between lithium and ", "from": "5618", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "626", "prefix": "e.g., ", "from": "614", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "carbamazepine", "suffix": ""}, {"to": "3994", "prefix": " 6 mg once daily with ", "from": "3982", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "carbamazepine", "suffix": ", a strong inducer of both CYP3A4 and P-glycoprotein "}, {"to": "4461", "prefix": "e CYP metabolism or bioavailability of paliperidone during ", "from": "4449", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "carbamazepine", "suffix": " co-administration. On initiation of carbamazepine, the dose"}, {"to": "4511", "prefix": "e during carbamazepine co-administration. On initiation of ", "from": "4499", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "carbamazepine", "suffix": ", the dose of INVEGA "}, {"to": "4631", "prefix": " increased if necessary. Conversely, on discontinuation of ", "from": "4619", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "carbamazepine", "suffix": ", the dose of INVEGA "}, {"to": "826", "prefix": "\n                           Co-administration of ", "from": "810", "name": "Divalproex Sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/266856", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "divalproex sodium", "suffix": " increased Cmax and AUC of paliperidone by approximately 50%"}, {"to": "2776", "prefix": " with ", "from": "2760", "name": "Divalproex Sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/266856", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "divalproex sodium", "suffix": " extended-release tablets "}, {"to": "5281", "prefix": " 12 mg with ", "from": "5265", "name": "Divalproex Sodium", "fullId": "http://purl.bioontology.org/ontology/RXNORM/266856", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "divalproex sodium", "suffix": " extended-release tablets "}, {"to": "2915", "prefix": " of ", "from": "2907", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": " in 13 patients stabilized on valproate. In a clinical study"}, {"to": "2954", "prefix": " of valproate in 13 patients stabilized on ", "from": "2946", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": ". In a clinical study, subjects on stable doses of valproate"}, {"to": "3014", "prefix": "alproate. In a clinical study, subjects on stable doses of ", "from": "3006", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": " had comparable valproate average plasma concentrations when"}, {"to": "3039", "prefix": "tudy, subjects on stable doses of valproate had comparable ", "from": "3031", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": " average plasma concentrations when INVEGA "}, {"to": "3132", "prefix": "day was added to their existing ", "from": "3124", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": " treatment.\n                     \n                     \n    "}, {"to": "5517", "prefix": " is co-administered with ", "from": "5509", "name": "Valproic Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D014635", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "valproate", "suffix": " after clinical assessment.\n                        Pharmaco"}, {"to": "1466", "prefix": "ugs and alcohol. Paliperidone may antagonize the effect of ", "from": "1459", "name": "Levodopa", "fullId": "http://purl.bioontology.org/ontology/MESH/D007980", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "levodopa", "suffix": " and other dopamine agonists.\n                        Becaus"}, {"to": "4968", "prefix": " was administered concomitantly with 20 mg per day of ", "from": "4959", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paroxetine", "suffix": " "}, {"to": "5124", "prefix": " higher in CYP2D6 extensive metabolizers. Higher doses of ", "from": "5115", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paroxetine", "suffix": " have not been studied. The clinical relevance is unknown.\n "}, {"to": "142", "prefix": "             \n                  The mechanism of action of ", "from": "132", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " is not precisely known. It does not act primarily by stimul"}, {"to": "319", "prefix": "a monoamine oxidase inhibitor. The postulated mechanism of ", "from": "309", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " is that it acts primarily by potentiation of central adrene"}, {"to": "431", "prefix": "ion of central adrenergic synapses by blocking reuptake of ", "from": "418", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "norepinephrine", "suffix": " at nerve endings. This pharmacologic action is thought to b"}, {"to": "330", "prefix": "                 CNS-Active Drugs \n                        ", "from": "324", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Ethanol", "suffix": ": Zaleplon 10 mg potentiated the CNS-impairing effects of et"}, {"to": "395", "prefix": "l: Zaleplon 10 mg potentiated the CNS-impairing effects of ", "from": "389", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ethanol", "suffix": " 0.75 g"}, {"to": "467", "prefix": "kg on balance testing and reaction time for 1 hour after ", "from": "461", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ethanol", "suffix": " administration and on the digit symbol substitution test "}, {"to": "641", "prefix": "omponent of the divided attention test for 2.5 hours after ", "from": "635", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ethanol", "suffix": " administration. The potentiation resulted from a CNS pharma"}, {"to": "779", "prefix": "teraction; zaleplon did not affect the pharmacokinetics of ", "from": "773", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ethanol", "suffix": ".\n                        Imipramine: Coadministration of si"}, {"to": "340", "prefix": "        CNS-Active Drugs \n                        Ethanol: ", "from": "333", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg potentiated the CNS-impairing effects of ethanol 0.75"}, {"to": "732", "prefix": "entiation resulted from a CNS pharmacodynamic interaction; ", "from": "725", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " did not affect the pharmacokinetics of ethanol.\n           "}, {"to": "861", "prefix": "           Imipramine: Coadministration of single doses of ", "from": "854", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 20 mg and imipramine 75 mg produced additive effects on dec"}, {"to": "1190", "prefix": "          Paroxetine: Coadministration of a single dose of ", "from": "1183", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 20 mg and paroxetine 20 mg daily for 7 days did not produce"}, {"to": "1366", "prefix": "tionally, paroxetine did not alter the pharmacokinetics of ", "from": "1359", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": ", reflecting the absence of a role of CYP2D6 in zaleplon's m"}, {"to": "1422", "prefix": "of Zaleplon, reflecting the absence of a role of CYP2D6 in ", "from": "1415", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": "'s metabolism.\n                        Thioridazine: Coadmin"}, {"to": "1519", "prefix": "         Thioridazine: Coadministration of single doses of ", "from": "1512", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 20 mg and thioridazine 50 mg produced additive effects on d"}, {"to": "1851", "prefix": "         Venlafaxine: Coadministration of a single dose of ", "from": "1844", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " 10 mg and multiple doses of venlafaxine ER "}, {"to": "2005", "prefix": " any significant changes in the pharmacokinetics of either ", "from": "1998", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " or venlafaxine. In addition, there was no pharmacodynamic i"}, {"to": "2119", "prefix": "macodynamic interaction as a result of coadministration of ", "from": "2112", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " and venlafaxine ER.\n                        Promethazine: C"}, {"to": "2223", "prefix": "        Promethazine: Coadministration of a single dose of ", "from": "2216", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " and promethazine "}, {"to": "2341", "prefix": "lted in a 15% decrease in maximal plasma concentrations of ", "from": "2334", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", but no change in the area under the plasma concentration-t"}, {"to": "2473", "prefix": "urve. However, the pharmacodynamics of coadministration of ", "from": "2466", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " and promethazine have not been evaluated. Caution should be"}, {"to": "2728", "prefix": "ampin: CYP3A4 is ordinarily a minor metabolizing enzyme of ", "from": "2721", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ". Multiple-dose administration of the potent CYP3A4 inducer "}, {"to": "2866", "prefix": ", however, reduced ", "from": "2859", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " Cmax and AUC by approximately 80%. The coadministration of "}, {"to": "3042", "prefix": "ng a safety concern, thus could lead to ineffectiveness of ", "from": "3035", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ". An alternative non-CYP3A4 substrate hypnotic agent may be "}, {"to": "3353", "prefix": "CYP3A4 is a minor metabolic pathway for the elimination of ", "from": "3346", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " because the sum of desethylzaleplon "}, {"to": "3560", "prefix": "curonide, account for only 9% of the urinary recovery of a ", "from": "3553", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " dose. Coadministration of single, oral doses of zaleplon wi"}, {"to": "3617", "prefix": "a zaleplon dose. Coadministration of single, oral doses of ", "from": "3610", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " with erythromycin "}, {"to": "3743", "prefix": "ng, selective CYP3A4 inhibitor, produced a 34% increase in ", "from": "3736", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": "'s maximal plasma concentrations and a 20% increase in the a"}, {"to": "4046", "prefix": "oconazole can also be expected to increase the exposure of ", "from": "4039", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ". A routine dosage adjustment of zaleplon is not considered "}, {"to": "4087", "prefix": "e the exposure of zaleplon. A routine dosage adjustment of ", "from": "4080", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is not considered necessary.\n                        Drugs "}, {"to": "4537", "prefix": "not known. There is no pharmacokinetic interaction between ", "from": "4530", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " and diphenhydramine following the administration of a singl"}, {"to": "5031", "prefix": "imary and secondary enzymes, respectively, responsible for ", "from": "5024", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " metabolism. Concomitant administration of Zaleplon "}, {"to": "5082", "prefix": "ble for zaleplon metabolism. Concomitant administration of ", "from": "5075", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "5176", "prefix": " produced an 85% increase in the mean Cmax and AUC of ", "from": "5169", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ". An initial dose of 5 mg should be given to patients who ar"}, {"to": "5409", "prefix": "gs Highly Bound to Plasma Protein \n                        ", "from": "5402", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is not highly bound to plasma proteins "}, {"to": "5513", "prefix": "; therefore, the disposition of ", "from": "5506", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is not expected to be sensitive to alterations in protein b"}, {"to": "5620", "prefix": "rations in protein binding. In addition, administration of ", "from": "5613", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " to a patient taking another drug that is highly protein bou"}, {"to": "5865", "prefix": "Narrow Therapeutic Index \n                        Digoxin: ", "from": "5858", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "6040", "prefix": ".\n                        Warfarin: Multiple oral doses of ", "from": "6033", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "6470", "prefix": " There was no apparent pharmacokinetic interaction between ", "from": "6463", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " and ibuprofen following single dose administration "}, {"to": "6603", "prefix": " of each drug. This was expected because ", "from": "6596", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is primarily metabolized and renal excretion of unchanged z"}, {"to": "6670", "prefix": " is primarily metabolized and renal excretion of unchanged ", "from": "6663", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " accounts for less than 1% of the administered dose.\n       "}, {"to": "815", "prefix": "t the pharmacokinetics of ethanol.\n                        ", "from": "806", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Imipramine", "suffix": ": Coadministration of single doses of Zaleplon 20 mg and imi"}, {"to": "882", "prefix": "ne: Coadministration of single doses of Zaleplon 20 mg and ", "from": "873", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "imipramine", "suffix": " 75 mg produced additive effects on decreased alertness and "}, {"to": "1143", "prefix": "e pharmacokinetics of either drug.\n                        ", "from": "1134", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Paroxetine", "suffix": ": Coadministration of a single dose of Zaleplon 20 mg and pa"}, {"to": "1211", "prefix": "e: Coadministration of a single dose of Zaleplon 20 mg and ", "from": "1202", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "paroxetine", "suffix": " 20 mg daily for 7 days did not produce any interaction on p"}, {"to": "1319", "prefix": " any interaction on psychomotor performance. Additionally, ", "from": "1310", "name": "Paroxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/32937", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "paroxetine", "suffix": " did not alter the pharmacokinetics of Zaleplon, reflecting "}, {"to": "1473", "prefix": "f CYP2D6 in zaleplon's metabolism.\n                        ", "from": "1462", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Thioridazine", "suffix": ": Coadministration of single doses of Zaleplon 20 mg and thi"}, {"to": "1542", "prefix": "ne: Coadministration of single doses of Zaleplon 20 mg and ", "from": "1531", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "thioridazine", "suffix": " 50 mg produced additive effects on decreased alertness and "}, {"to": "1804", "prefix": "e pharmacokinetics of either drug.\n                        ", "from": "1794", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Venlafaxine", "suffix": ": Coadministration of a single dose of zaleplon 10 mg and mu"}, {"to": "1891", "prefix": "n of a single dose of zaleplon 10 mg and multiple doses of ", "from": "1881", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "venlafaxine", "suffix": " ER "}, {"to": "2020", "prefix": "cant changes in the pharmacokinetics of either zaleplon or ", "from": "2010", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "venlafaxine", "suffix": ". In addition, there was no pharmacodynamic interaction as a"}, {"to": "2135", "prefix": "nteraction as a result of coadministration of zaleplon and ", "from": "2125", "name": "venlafaxine", "fullId": "http://purl.bioontology.org/ontology/MESH/C047426", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "venlafaxine", "suffix": " ER.\n                        Promethazine: Coadministration "}, {"to": "2176", "prefix": "on of zaleplon and venlafaxine ER.\n                        ", "from": "2165", "name": "Promethazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8745", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Promethazine", "suffix": ": Coadministration of a single dose of zaleplon and prometha"}, {"to": "2240", "prefix": "thazine: Coadministration of a single dose of zaleplon and ", "from": "2229", "name": "Promethazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8745", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "promethazine", "suffix": " "}, {"to": "2490", "prefix": ", the pharmacodynamics of coadministration of zaleplon and ", "from": "2479", "name": "Promethazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8745", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "promethazine", "suffix": " have not been evaluated. Caution should be exercised when t"}, {"to": "2666", "prefix": "         Drugs That Induce CYP3A4 \n                        ", "from": "2659", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Rifampin", "suffix": ": CYP3A4 is ordinarily a minor metabolizing enzyme of zalepl"}, {"to": "2796", "prefix": " Multiple-dose administration of the potent CYP3A4 inducer ", "from": "2789", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "rifampin", "suffix": " "}, {"to": "3164", "prefix": "y be considered in patients taking CYP3A4 inducers such as ", "from": "3157", "name": "Rifampin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/9384", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "rifampin", "suffix": ", phenytoin, carbamazepine, and phenobarbital.\n             "}, {"to": "3175", "prefix": "dered in patients taking CYP3A4 inducers such as rifampin, ", "from": "3167", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "phenytoin", "suffix": ", carbamazepine, and phenobarbital.\n                        "}, {"to": "3190", "prefix": "tients taking CYP3A4 inducers such as rifampin, phenytoin, ", "from": "3178", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "carbamazepine", "suffix": ", and phenobarbital.\n                        Drugs That Inhi"}, {"to": "3209", "prefix": "4 inducers such as rifampin, phenytoin, carbamazepine, and ", "from": "3197", "name": "Phenobarbital", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8134", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "phenobarbital", "suffix": ".\n                        Drugs That Inhibit CYP3A4 \n       "}, {"to": "3635", "prefix": "e. Coadministration of single, oral doses of zaleplon with ", "from": "3624", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "erythromycin", "suffix": " "}, {"to": "3914", "prefix": "curve. The magnitude of interaction with multiple doses of ", "from": "3903", "name": "Erythromycin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004917", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "erythromycin", "suffix": " is unknown. Other strong selective CYP3A4 inhibitors such a"}, {"to": "3988", "prefix": " unknown. Other strong selective CYP3A4 inhibitors such as ", "from": "3977", "name": "Ketoconazole", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6135", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ketoconazole", "suffix": " can also be expected to increase the exposure of zaleplon. "}, {"to": "4337", "prefix": "the cytochrome P450 enzyme system.\n                        ", "from": "4323", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3498", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Diphenhydramine", "suffix": ": Diphenhydramine is reported to be a weak inhibitor of alde"}, {"to": "4354", "prefix": "50 enzyme system.\n                        Diphenhydramine: ", "from": "4340", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3498", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Diphenhydramine", "suffix": " is reported to be a weak inhibitor of aldehyde oxidase in r"}, {"to": "4557", "prefix": "ere is no pharmacokinetic interaction between zaleplon and ", "from": "4543", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3498", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "diphenhydramine", "suffix": " following the administration of a single dose "}, {"to": "4868", "prefix": " Both Aldehyde Oxidase and CYP3A4 \n                        ", "from": "4859", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Cimetidine", "suffix": ": Cimetidine inhibits both aldehyde oxidase "}, {"to": "4880", "prefix": "de Oxidase and CYP3A4 \n                        Cimetidine: ", "from": "4871", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Cimetidine", "suffix": " inhibits both aldehyde oxidase "}, {"to": "5105", "prefix": " and ", "from": "5096", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "cimetidine", "suffix": " "}, {"to": "5281", "prefix": "given to patients who are concomitantly being treated with ", "from": "5272", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "cimetidine", "suffix": " "}, {"to": "5855", "prefix": "s with a Narrow Therapeutic Index \n                        ", "from": "5849", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Digoxin", "suffix": ": Zaleplon "}, {"to": "5946", "prefix": "t affect the pharmacokinetic or pharmacodynamic profile of ", "from": "5940", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "digoxin", "suffix": " "}, {"to": "6007", "prefix": ".\n                        ", "from": "6000", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Warfarin", "suffix": ": Multiple oral doses of Zaleplon "}, {"to": "6113", "prefix": " did not affect the pharmacokinetics of ", "from": "6106", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "warfarin", "suffix": " "}, {"to": "6229", "prefix": " following a single 25-mg oral dose of ", "from": "6222", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "warfarin", "suffix": ".\n                        Drugs That Alter Renal Excretion I"}, {"to": "6176", "prefix": "", "from": "6166", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "prothrombin", "suffix": " time"}, {"to": "6297", "prefix": ".\n                        Drugs That Alter Renal Excretion ", "from": "6289", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Ibuprofen", "suffix": ": Ibuprofen is known to affect renal function and, consequen"}, {"to": "6308", "prefix": "               Drugs That Alter Renal Excretion Ibuprofen: ", "from": "6300", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Ibuprofen", "suffix": " is known to affect renal function and, consequently, alter "}, {"to": "6484", "prefix": " apparent pharmacokinetic interaction between zaleplon and ", "from": "6476", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ibuprofen", "suffix": " following single dose administration "}, {"to": "272", "prefix": "sm of Action\n                     \n                        ", "from": "261", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is the major active metabolite of risperidone. The mechanis"}, {"to": "359", "prefix": "tive metabolite of risperidone. The mechanism of action of ", "from": "348", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": ", as with other drugs having efficacy in schizophrenia, is u"}, {"to": "881", "prefix": "macodynamics\n                     \n                        ", "from": "870", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is a centrally active dopamine Type 2 "}, {"to": "1004", "prefix": " activity. ", "from": "993", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " is also active as an antagonist at "}, {"to": "1172", "prefix": ", which may explain some of the other effects of the drug. ", "from": "1161", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " has no affinity for cholinergic muscarinic or "}, {"to": "1314", "prefix": "- ", "from": "1303", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " enantiomers is qualitatively and quantitatively similar in "}, {"to": "1719", "prefix": "     Following a single dose, the plasma concentrations of ", "from": "1708", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " gradually rise to reach peak plasma concentration "}, {"to": "1850", "prefix": "proximately 24 hours after dosing. The pharmacokinetics of ", "from": "1839", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " following INVEGA "}, {"to": "1989", "prefix": "vailable dose range. The terminal elimination half-life of ", "from": "1978", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is approximately 23 hours.\n                        Steady-s"}, {"to": "2084", "prefix": "rs.\n                        Steady-state concentrations of ", "from": "2073", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " are attained within 4"}, {"to": "2360", "prefix": " enantiomers of ", "from": "2349", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " interconvert, reaching an AUC "}, {"to": "2823", "prefix": "                      The absolute oral bioavailability of ", "from": "2812", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " following INVEGA "}, {"to": "2933", "prefix": "%.\n                              Administration of a 12 mg ", "from": "2922", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " extended-release tablet to healthy ambulatory subjects with"}, {"to": "3077", "prefix": "high-caloric meal gave mean Cmax and AUC values of ", "from": "3066", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " that were increased by 60% and 54%, respectively, compared "}, {"to": "3462", "prefix": " administration may increase exposure to ", "from": "3451", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " [see Dosage and Administration "}, {"to": "3615", "prefix": "opulation analysis, the apparent volume of distribution of ", "from": "3604", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is 487 L. The plasma protein binding of racemic paliperidon"}, {"to": "3676", "prefix": "liperidone is 487 L. The plasma protein binding of racemic ", "from": "3665", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is 74%.\n                           \n                       "}, {"to": "4278", "prefix": "isozymes play a limited role in the overall elimination of ", "from": "4267", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " [see Drug Interactions "}, {"to": "4436", "prefix": "ration of a single oral dose of 1 mg immediate-release 14C-", "from": "4425", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " to 5 healthy volunteers, 59% "}, {"to": "5063", "prefix": "c analyses found no difference in exposure or clearance of ", "from": "5052", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " between extensive metabolizers and poor metabolizers of CYP"}, {"to": "6046", "prefix": "]. The disposition of a single dose ", "from": "6035", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " 3 mg extended-release tablet was studied in adult subjects "}, {"to": "6173", "prefix": "cts with varying degrees of renal function. Elimination of ", "from": "6162", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " decreased with decreasing estimated creatinine clearance. T"}, {"to": "6263", "prefix": "reasing estimated creatinine clearance. Total clearance of ", "from": "6252", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " was reduced in subjects with impaired renal function by 32%"}, {"to": "6693", "prefix": "althy subjects. The mean terminal elimination half-life of ", "from": "6682", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " was 24 hours, 40 hours, and 51 hours in subjects with mild,"}, {"to": "7475", "prefix": ", the plasma concentrations of free ", "from": "7464", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " were similar to those of healthy subjects, although total p"}, {"to": "7546", "prefix": " were similar to those of healthy subjects, although total ", "from": "7535", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " exposure decreased because of a decrease in protein binding"}, {"to": "8262", "prefix": "                      \n                                    ", "from": "8251", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "Paliperidone", "suffix": " systemic exposure in adolescents weighing "}, {"to": "8528", "prefix": "ot to be clinically significant. Age did not influence the ", "from": "8517", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " exposure.\n                                 \n               "}, {"to": "10992", "prefix": ". Based on in vitro studies utilizing human liver enzymes, ", "from": "10981", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": " is not a substrate for CYP1A2; smoking should, therefore, n"}, {"to": "11109", "prefix": ", therefore, not have an effect on the pharmacokinetics of ", "from": "11098", "name": "paliperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/679314", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "paliperidone", "suffix": ".\n                                 \n                        "}, {"to": "1867", "prefix": "ter dosing. The pharmacokinetics of paliperidone following ", "from": "1862", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "2135", "prefix": "5 days of dosing with ", "from": "2130", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "2208", "prefix": "t subjects. The mean steady-state peak:trough ratio for an ", "from": "2203", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "2314", "prefix": "3.1.\n                        Following administration of ", "from": "2309", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "2840", "prefix": "he absolute oral bioavailability of paliperidone following ", "from": "2835", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3245", "prefix": "s. Clinical trials establishing the safety and efficacy of ", "from": "3240", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3327", "prefix": "t in subjects without regard to the timing of meals. While ", "from": "3322", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "3408", "prefix": "ithout regard to food, the presence of food at the time of ", "from": "3403", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "5889", "prefix": "          \n                                    The dose of ", "from": "5884", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "7713", "prefix": "ired in patients with mild or moderate hepatic impairment. ", "from": "7708", "name": "9-hydroxy-risperidone", "fullId": "http://purl.bioontology.org/ontology/MESH/C079150", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "INVEGA", "suffix": " "}, {"to": "318", "prefix": "            Paliperidone is the major active metabolite of ", "from": "308", "name": "Risperidone", "fullId": "http://purl.bioontology.org/ontology/RXNORM/35636", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "risperidone", "suffix": ". The mechanism of action of paliperidone, as with other dru"}, {"to": "559", "prefix": "schizophrenia is mediated through a combination of central ", "from": "552", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "dopamine", "suffix": " Type 2 "}, {"to": "912", "prefix": "                        Paliperidone is a centrally active ", "from": "905", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "dopamine", "suffix": " Type 2 "}, {"to": "585", "prefix": " and ", "from": "577", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "serotonin", "suffix": " Type 2 "}, {"to": "966", "prefix": " antagonist and with predominant ", "from": "958", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "serotonin", "suffix": " Type 2 "}, {"to": "6220", "prefix": "nation of paliperidone decreased with decreasing estimated ", "from": "6211", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "creatinine", "suffix": " clearance. Total clearance of paliperidone was reduced in s"}, {"to": "9127", "prefix": "stment may be required because of age-related decreases in ", "from": "9118", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "7b8e5b26-b9e4-4704-921b-3c3c0d159916", "exact": "creatinine", "suffix": " clearance [see Renal Impairment above and Dosage and Admini"}, {"to": "114", "prefix": "    7 DRUG INTERACTIONS\n\n               \n                  ", "from": "104", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " undergoes minimal CYP450 related metabolism, with the major"}, {"to": "321", "prefix": ". In vitro and in vivo studies showed that ", "from": "315", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " is unlikely to be involved in clinically significant pharma"}, {"to": "612", "prefix": "      \n                        \n                           ", "from": "606", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " is unlikely to be involved in clinically significant pharma"}, {"to": "772", "prefix": "                           Pharmacodynamic interactions of ", "from": "766", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " with other drugs can occur "}, {"to": "1990", "prefix": "use of an SSRI and a triptan.  If concomitant treatment of ", "from": "1984", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " with a triptan is clinically warranted, careful observation"}, {"to": "2429", "prefix": "echolamines\n\n                     \n                        ", "from": "2423", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " inhibits the reuptake of norepinephrine. Therefore concomit"}, {"to": "2507", "prefix": "e reuptake of norepinephrine. Therefore concomitant use of ", "from": "2501", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " with epinephrine and norepinephrine may be associated with "}, {"to": "2946", "prefix": " \n                        Given the primary CNS effects of ", "from": "2940", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": ", caution should be used when it is taken in combination wit"}, {"to": "3306", "prefix": "was observed in patients who switched from clomipramine to ", "from": "3300", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": ".\n\n                     \n                     \n             "}, {"to": "3630", "prefix": "                  \n                        Digoxin: Use of ", "from": "3624", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " concomitantly with digoxin may be associated with potentiat"}, {"to": "3881", "prefix": ". Co-administration of ", "from": "3875", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " and intravenous digoxin should be avoided [see Warnings and"}, {"to": "4046", "prefix": "            \n                           Clonidine: Because ", "from": "4040", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " inhibits norepinephrine reuptake, co-administration with cl"}, {"to": "1909", "prefix": "             There have been rare postmarketing reports of ", "from": "1901", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "serotonin", "suffix": " syndrome with use of an SSRI and a triptan.  If concomitant"}, {"to": "2469", "prefix": " \n                        Savella inhibits the reuptake of ", "from": "2456", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "norepinephrine", "suffix": ". Therefore concomitant use of Savella with epinephrine and "}, {"to": "2543", "prefix": " Therefore concomitant use of Savella with epinephrine and ", "from": "2530", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "norepinephrine", "suffix": " may be associated with paroxysmal hypertension and possible"}, {"to": "4070", "prefix": "                       Clonidine: Because Savella inhibits ", "from": "4057", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/MESH/D009638", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "norepinephrine", "suffix": " reuptake, co-administration with clonidine may inhibit clon"}, {"to": "2524", "prefix": " norepinephrine. Therefore concomitant use of Savella with ", "from": "2514", "name": "Epinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3992", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "epinephrine", "suffix": " and norepinephrine may be associated with paroxysmal hypert"}, {"to": "3155", "prefix": "tion.\n\n                        \n                           ", "from": "3144", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Clomipramine", "suffix": ": In a drug-drug interaction study, an increase in euphoria "}, {"to": "3295", "prefix": "ral hypotension was observed in patients who switched from ", "from": "3284", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "clomipramine", "suffix": " to Savella.\n\n                     \n                     \n  "}, {"to": "3614", "prefix": "ular Agents\n\n                     \n                        ", "from": "3608", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Digoxin", "suffix": ": Use of Savella concomitantly with digoxin may be associate"}, {"to": "3657", "prefix": "                Digoxin: Use of Savella concomitantly with ", "from": "3651", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "digoxin", "suffix": " may be associated with potentiation of adverse hemodynamic "}, {"to": "3844", "prefix": "ted in combination therapy with intravenously administered ", "from": "3838", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "digoxin", "suffix": " "}, {"to": "3905", "prefix": ". Co-administration of Savella and intravenous ", "from": "3899", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "digoxin", "suffix": " should be avoided [see Warnings and Precautions "}, {"to": "4029", "prefix": "].\n\n                        \n                           ", "from": "4021", "name": "Clonidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003000", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Clonidine", "suffix": ": Because Savella inhibits norepinephrine reuptake, co-admin"}, {"to": "4113", "prefix": "a inhibits norepinephrine reuptake, co-administration with ", "from": "4105", "name": "Clonidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003000", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "clonidine", "suffix": " may inhibit clonidine's anti-hypertensive effect.\n\n        "}, {"to": "4135", "prefix": "ine reuptake, co-administration with clonidine may inhibit ", "from": "4127", "name": "Clonidine", "fullId": "http://purl.bioontology.org/ontology/MESH/D003000", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "clonidine", "suffix": "'s anti-hypertensive effect.\n\n                     \n        "}, {"to": "334", "prefix": "e exact mechanism of the central pain inhibitory action of ", "from": "324", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " and its ability to improve the symptoms of fibromyalgia in "}, {"to": "461", "prefix": "in humans are unknown. Preclinical studies have shown that ", "from": "451", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " is a potent inhibitor of neuronal norepinephrine and seroto"}, {"to": "546", "prefix": "hibitor of neuronal norepinephrine and serotonin reuptake; ", "from": "536", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " inhibits norepinephrine uptake with approximately 3-fold hi"}, {"to": "732", "prefix": "fecting the uptake of dopamine or other neurotransmitters. ", "from": "722", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " has no significant affinity for serotonergic "}, {"to": "1157", "prefix": "en with other psychotropic drugs.\n\n                        ", "from": "1147", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " has no significant affinity for Ca"}, {"to": "1657", "prefix": "            Cardiovascular Electrophysiology-The effect of ", "from": "1651", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " on the QTcF interval was measured in a double-blind placebo"}, {"to": "1805", "prefix": "day ", "from": "1799", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " "}, {"to": "2298", "prefix": "acokinetics\n\n                     \n                        ", "from": "2288", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " is well absorbed after oral administration with an absolute"}, {"to": "2431", "prefix": "oavailability of approximately 85% to 90%. The exposure to ", "from": "2421", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " increased proportionally within the therapeutic dose range."}, {"to": "2744", "prefix": " predicted from single-dose data. The active enantiomer, d-", "from": "2734", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ", has a longer elimination half-life "}, {"to": "3218", "prefix": "                            \n                              ", "from": "3212", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " is absorbed following oral administration with maximum conc"}, {"to": "3356", "prefix": " reached within 2 to 4 hours post dose. Absorption of ", "from": "3350", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " is not affected by food. The absolute bioavailability is ap"}, {"to": "3486", "prefix": "proximately 85% to 90%. The mean volume of distribution of ", "from": "3476", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " following a single intravenous dose to healthy subjects is "}, {"to": "4027", "prefix": "                            \n                              ", "from": "4017", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " and its metabolites are eliminated primarily by renal excre"}, {"to": "4155", "prefix": "y by renal excretion. Following oral administration of 14C-", "from": "4131", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran hydrochloride", "suffix": ", approximately 55% of the dose was excreted in urine as unc"}, {"to": "4233", "prefix": "imately 55% of the dose was excreted in urine as unchanged ", "from": "4223", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " "}, {"to": "4255", "prefix": "24% as l-", "from": "4245", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " and 31% as d-milnacipran"}, {"to": "4280", "prefix": "24% as l-milnacipran and 31% as d-", "from": "4270", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ""}, {"to": "4300", "prefix": ". The l-", "from": "4290", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " carbamoyl-O-glucuronide was the major metabolite excreted i"}, {"to": "4484", "prefix": "e; approximately 2% of the dose was excreted in urine as d-", "from": "4474", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " carbamoyl-O-glucuronide. Approximately 8% of the dose was e"}, {"to": "4590", "prefix": "ely 8% of the dose was excreted in urine as the N-desethyl ", "from": "4580", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " metabolite.\n\n                           \n                  "}, {"to": "5294", "prefix": "  \n                                       Renal Impairment-", "from": "5284", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " pharmacokinetics were evaluated following single oral admin"}, {"to": "5380", "prefix": "re evaluated following single oral administration of 50 mg ", "from": "5374", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " to subjects with mild "}, {"to": "6475", "prefix": "\n                                       Hepatic Impairment-", "from": "6465", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Milnacipran", "suffix": " pharmacokinetics were evaluated following single oral admin"}, {"to": "6561", "prefix": "re evaluated following single oral administration of 50 mg ", "from": "6555", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " to subjects with mild "}, {"to": "7397", "prefix": "                        Elderly-Cmax and AUC parameters of ", "from": "7387", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " were about 30% higher in elderly "}, {"to": "8106", "prefix": "                         Gender-Cmax and AUC parameters of ", "from": "8096", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " were about 20% higher in female subjects compared with male"}, {"to": "8679", "prefix": "- In a pharmacokinetic study, a single, oral dose of 50 mg ", "from": "8669", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " HCl tablet was administered to 8 lactating women who were a"}, {"to": "8849", "prefix": "their infants. The maximum estimated daily infant dose for ", "from": "8839", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " from breast milk "}, {"to": "9034", "prefix": "a concentrations. In most patients, peak concentrations of ", "from": "9024", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " in breast milk were seen within 4 hours after the maternal "}, {"to": "9165", "prefix": "  Because of the limited data regarding infant exposure to ", "from": "9159", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": ", caution should be exercised when Savella is administered t"}, {"to": "9207", "prefix": "fant exposure to Savella, caution should be exercised when ", "from": "9201", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " is administered to a nursing woman.\n\n                      "}, {"to": "10074", "prefix": "          \n                                    In general, ", "from": "10064", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ", at concentrations that were at least 25 times those attain"}, {"to": "10560", "prefix": "itro studies have shown that the biotransformation rate of ", "from": "10550", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " by human hepatic microsomes and hepatocytes was low. A low "}, {"to": "10691", "prefix": "iotransformation was also observed following incubation of ", "from": "10681", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " with cDNA-expressed human CYP1A2, CYP2A6, CYP2B6, CYP2C9, C"}, {"to": "11481", "prefix": " clinically significant changes in the pharmacokinetics of ", "from": "11471", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " following co-administration of Savella "}, {"to": "11520", "prefix": "macokinetics of milnacipran following co-administration of ", "from": "11514", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " "}, {"to": "11703", "prefix": "ne or its epoxide metabolite due to co-administration with ", "from": "11697", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": ".\n\n                                    Clomipramine-Switchin"}, {"to": "11816", "prefix": " to ", "from": "11806", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " "}, {"to": "11940", "prefix": " clinically significant changes in the pharmacokinetics of ", "from": "11930", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ". Because an increase in adverse events "}, {"to": "12081", "prefix": " was observed after switching from clomipramine to ", "from": "12071", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ", monitoring of patients during treatment switch is recommen"}, {"to": "12247", "prefix": "  Digoxin-There was no pharmacokinetic interaction between ", "from": "12241", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " "}, {"to": "12568", "prefix": "nhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, to ", "from": "12558", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " "}, {"to": "12657", "prefix": "ut a washout period did not affect the pharmacokinetics of ", "from": "12647", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": ".\n\n                                    Lithium-Multiple dose"}, {"to": "12729", "prefix": "                                 Lithium-Multiple doses of ", "from": "12723", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " "}, {"to": "12911", "prefix": "as no pharmacokinetic interaction between a single dose of ", "from": "12905", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " "}, {"to": "13088", "prefix": "ignificant changes in the steady-state pharmacokinetics of ", "from": "13078", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " or pregabalin following twice a day co-administration of 50"}, {"to": "13163", "prefix": "regabalin following twice a day co-administration of 50 mg ", "from": "13153", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " and 150  mg pregabalin.\n\n                                   "}, {"to": "13257", "prefix": "\n                                    Warfarin-Steady-state ", "from": "13247", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "milnacipran", "suffix": " "}, {"to": "13475", "prefix": "f a single dose of 25 mg warfarin. The pharmacokinetics of ", "from": "13469", "name": "milnacipran", "fullId": "http://purl.bioontology.org/ontology/MESH/C048107", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Savella", "suffix": " were not altered by warfarin.\n\n                            "}, {"to": "510", "prefix": "e shown that milnacipran is a potent inhibitor of neuronal ", "from": "497", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "norepinephrine", "suffix": " and serotonin reuptake; milnacipran inhibits norepinephrine"}, {"to": "570", "prefix": "orepinephrine and serotonin reuptake; milnacipran inhibits ", "from": "557", "name": "Norepinephrine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/7512", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "norepinephrine", "suffix": " uptake with approximately 3-fold higher potency in vitro th"}, {"to": "524", "prefix": "ipran is a potent inhibitor of neuronal norepinephrine and ", "from": "516", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "serotonin", "suffix": " reuptake; milnacipran inhibits norepinephrine uptake with a"}, {"to": "642", "prefix": "ake with approximately 3-fold higher potency in vitro than ", "from": "634", "name": "Serotonin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1311214", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "serotonin", "suffix": " without directly affecting the uptake of dopamine or other "}, {"to": "692", "prefix": "ro than serotonin without directly affecting the uptake of ", "from": "685", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "dopamine", "suffix": " or other neurotransmitters. Milnacipran has no significant "}, {"to": "855", "prefix": ", ", "from": "848", "name": "Dopamine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3628", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "dopamine", "suffix": " "}, {"to": "838", "prefix": ", ", "from": "830", "name": "Histamine", "fullId": "http://purl.bioontology.org/ontology/MESH/D006632", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "histamine", "suffix": " "}, {"to": "886", "prefix": ", opiate, ", "from": "873", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "benzodiazepine", "suffix": ", and "}, {"to": "911", "prefix": "-", "from": "895", "name": "Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/RXNORM/70582", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "aminobutyric acid", "suffix": " "}, {"to": "917", "prefix": "", "from": "914", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "GABA", "suffix": ""}, {"to": "5414", "prefix": "", "from": "5405", "name": "Creatinine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2913", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "creatinine", "suffix": " clearance [CLcr] 50-80 mL"}, {"to": "11397", "prefix": "althy adult subjects.\n\n                                    ", "from": "11385", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Carbamazepine", "suffix": "-There were no clinically significant changes in the pharmac"}, {"to": "11551", "prefix": " and ", "from": "11539", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "carbamazepine", "suffix": " "}, {"to": "11639", "prefix": ". No changes were observed in the pharmacokinetics of ", "from": "11627", "name": "Carbamazepine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2002", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "carbamazepine", "suffix": " or its epoxide metabolite due to co-administration with Sav"}, {"to": "11754", "prefix": "tration with Savella.\n\n                                    ", "from": "11743", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Clomipramine", "suffix": "-Switching from clomipramine "}, {"to": "11782", "prefix": "                               Clomipramine-Switching from ", "from": "11771", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "clomipramine", "suffix": " "}, {"to": "12066", "prefix": " was observed after switching from ", "from": "12055", "name": "Clomipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2597", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "clomipramine", "suffix": " to milnacipran, monitoring of patients during treatment swi"}, {"to": "12190", "prefix": "witch is recommended.\n\n                                    ", "from": "12184", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Digoxin", "suffix": "-There was no pharmacokinetic interaction between Savella "}, {"to": "12272", "prefix": " and ", "from": "12266", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "digoxin", "suffix": "\n\n                                    "}, {"to": "12332", "prefix": "day ", "from": "12323", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/MESH/D004077", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Lanoxicaps", "suffix": ""}, {"to": "12441", "prefix": " to healthy subjects.\n\n                                    ", "from": "12432", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Fluoxetine", "suffix": "-Switching from fluoxetine "}, {"to": "12467", "prefix": "                                 Fluoxetine-Switching from ", "from": "12458", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/MESH/D005473", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "fluoxetine", "suffix": " "}, {"to": "12837", "prefix": "okinetics of lithium.\n\n                                    ", "from": "12829", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008140", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Lorazepam", "suffix": "-There was no pharmacokinetic interaction between a single d"}, {"to": "12933", "prefix": " and ", "from": "12925", "name": "Lorazepam", "fullId": "http://purl.bioontology.org/ontology/MESH/D008140", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "lorazepam", "suffix": " "}, {"to": "12991", "prefix": ".\n\n                                    ", "from": "12982", "name": "pregabalin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/187832", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Pregabalin", "suffix": "-There were no clinically significant changes in the steady-"}, {"to": "13102", "prefix": "ges in the steady-state pharmacokinetics of milnacipran or ", "from": "13093", "name": "pregabalin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/187832", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "pregabalin", "suffix": " following twice a day co-administration of 50 mg milnacipra"}, {"to": "13185", "prefix": "ce a day co-administration of 50 mg milnacipran and 150  mg ", "from": "13176", "name": "pregabalin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/187832", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "pregabalin", "suffix": ".\n\n                                    Warfarin-Steady-state"}, {"to": "13232", "prefix": "nd 150  mg pregabalin.\n\n                                    ", "from": "13225", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "Warfarin", "suffix": "-Steady-state milnacipran "}, {"to": "13320", "prefix": " did not affect the pharmacokinetics of R-", "from": "13313", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "warfarin", "suffix": " and S-warfarin or the pharmacodynamics "}, {"to": "13335", "prefix": " did not affect the pharmacokinetics of R-warfarin and S-", "from": "13328", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "warfarin", "suffix": " or the pharmacodynamics "}, {"to": "13442", "prefix": " of a single dose of 25 mg ", "from": "13435", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "warfarin", "suffix": ". The pharmacokinetics of Savella were not altered by warfar"}, {"to": "13504", "prefix": "farin. The pharmacokinetics of Savella were not altered by ", "from": "13497", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "warfarin", "suffix": ".\n\n                                 \n                       "}, {"to": "13402", "prefix": "as assessed by measurement of ", "from": "13392", "name": "Prothrombin", "fullId": "http://purl.bioontology.org/ontology/MESH/D011516", "setId": "16a4a314-f97e-4e91-95e9-576a3773d284", "exact": "prothrombin", "suffix": " INR"}, {"to": "218", "prefix": "anism of Action\n                  \n                  While ", "from": "211", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is a hypnotic agent with a chemical structure unrelated to "}, {"to": "797", "prefix": "           \nOther nonclinical studies have also shown that ", "from": "790", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " binds selectively to the brain omega-1 receptor situated on"}, {"to": "1022", "prefix": " binding. Studies of binding of ", "from": "1015", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " to recombinant GABAA receptors "}, {"to": "1118", "prefix": " have shown that ", "from": "1111", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " has a low affinity for these receptors, with preferential b"}, {"to": "1337", "prefix": "                \n                  The pharmacokinetics of ", "from": "1330", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " have been investigated in more than 500 healthy subjects "}, {"to": "1656", "prefix": " once-daily administration at 15 mg and 30 mg for 10 days. ", "from": "1649", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " was rapidly absorbed with a time to peak concentration "}, {"to": "1826", "prefix": " of approximately 1 hour. ", "from": "1819", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " does not accumulate with once-daily administration and its "}, {"to": "2007", "prefix": "tic range.\n                  Absorption \n                  ", "from": "2000", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is rapidly and almost completely absorbed following oral ad"}, {"to": "2193", "prefix": "n approximately 1 hour after oral administration. Although ", "from": "2186", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is well absorbed, its absolute bioavailability is approxima"}, {"to": "2377", "prefix": "abolism.\n                  Distribution \n                  ", "from": "2370", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is a lipophilic compound with a volume of distribution of a"}, {"to": "2657", "prefix": "15% and is independent of ", "from": "2650", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " concentration over the range of 10 ng"}, {"to": "2741", "prefix": "mL. This suggests that ", "from": "2734", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " disposition should not be sensitive to alterations in prote"}, {"to": "2851", "prefix": "erations in protein binding. The blood to plasma ratio for ", "from": "2844", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is approximately 1, indicating that zaleplon is uniformly d"}, {"to": "2896", "prefix": "sma ratio for zaleplon is approximately 1, indicating that ", "from": "2889", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is uniformly distributed throughout the blood with no exten"}, {"to": "3078", "prefix": "   Metabolism\n                  After oral administration, ", "from": "3071", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is extensively metabolized, with less than 1% of the dose e"}, {"to": "3174", "prefix": "with less than 1% of the dose excreted unchanged in urine. ", "from": "3167", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is primarily metabolized by aldehyde oxidase to form 5-oxo-"}, {"to": "3242", "prefix": "is primarily metabolized by aldehyde oxidase to form 5-oxo-", "from": "3235", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ". Zaleplon is metabolized to a lesser extent by cytochrome P"}, {"to": "3252", "prefix": "ly metabolized by aldehyde oxidase to form 5-oxo-zaleplon. ", "from": "3245", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is metabolized to a lesser extent by cytochrome P450 "}, {"to": "3341", "prefix": " 3A4 to form desethyl ", "from": "3334", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", which is quickly converted, presumably by aldehyde oxidase"}, {"to": "3533", "prefix": " converted to glucuronides and eliminated in urine. All of ", "from": "3526", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": "'s metabolites are pharmacologically inactive.\n             "}, {"to": "3677", "prefix": "\n                  After either oral or IV administration, ", "from": "3670", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is rapidly eliminated with a mean t1"}, {"to": "3784", "prefix": "of approximately 1 hour. The oral-dose plasma clearance of ", "from": "3777", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is about 3 L"}, {"to": "3822", "prefix": "kg and the IV ", "from": "3815", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " plasma clearance is approximately 1 L"}, {"to": "3944", "prefix": "ormal hepatic blood flow and negligible renal clearance of ", "from": "3937", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", the estimated hepatic extraction ratio of zaleplon is appr"}, {"to": "3996", "prefix": "nce of zaleplon, the estimated hepatic extraction ratio of ", "from": "3989", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is approximately 0.7, indicating that zaleplon is subject t"}, {"to": "4043", "prefix": "on ratio of zaleplon is approximately 0.7, indicating that ", "from": "4036", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is subject to high first-pass metabolism.\n                 "}, {"to": "4160", "prefix": "           After administration of a radio labeled dose of ", "from": "4153", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", 70% of the administered dose is recovered in urine within "}, {"to": "4282", "prefix": ", almost all as ", "from": "4275", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " metabolites and their glucuronides. An additional 17% is re"}, {"to": "4396", "prefix": "nal 17% is recovered in feces within 6 days, most as 5-oxo-", "from": "4389", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ".\n                  Effect of Food \n                  In hea"}, {"to": "4526", "prefix": "heavy meal prolonged the absorption of ", "from": "4519", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " compared to the fasted state, delaying tmax by approximatel"}, {"to": "4644", "prefix": "roximately 2 hours and reducing Cmax by approximately 35%. ", "from": "4637", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " AUC and elimination half-life were not significantly affect"}, {"to": "4758", "prefix": "cantly affected. These results suggest that the effects of ", "from": "4751", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " on sleep onset may be reduced if it is taken with or immedi"}, {"to": "4947", "prefix": "opulations \n                  Age: The pharmacokinetics of ", "from": "4940", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " have been investigated in three studies with elderly men an"}, {"to": "5083", "prefix": "anging in age from 65 to 85 years. The pharmacokinetics of ", "from": "5076", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " in elderly subjects, including those over 75 years of age, "}, {"to": "5309", "prefix": "re is no significant difference in the pharmacokinetics of ", "from": "5302", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " in men and women.\n                  Race: The pharmacokinet"}, {"to": "5384", "prefix": "and women.\n                  Race: The pharmacokinetics of ", "from": "5377", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " have been studied in Japanese subjects as representative of"}, {"to": "5894", "prefix": " well characterized.\n                  Hepatic impairment: ", "from": "5887", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is metabolized primarily by the liver and undergoes signifi"}, {"to": "6027", "prefix": "resystemic metabolism. Consequently, the oral clearance of ", "from": "6020", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " was reduced by 70% and 87% in compensated and decompensated"}, {"to": "6311", "prefix": ", in comparison with healthy subjects. The dose of ", "from": "6304", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " should therefore be reduced in patients with mild to modera"}, {"to": "6434", "prefix": ". ", "from": "6427", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " is not recommended for use in patients with severe hepatic "}, {"to": "6587", "prefix": "    Renal impairment: Because renal excretion of unchanged ", "from": "6580", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " accounts for less than 1% of the administered dose, the pha"}, {"to": "6672", "prefix": " than 1% of the administered dose, the pharmacokinetics of ", "from": "6665", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " are not altered in patients with renal insufficiency. No do"}, {"to": "6819", "prefix": "essary in patients with mild to moderate renal impairment. ", "from": "6812", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " has not been adequately studied in patients with severe ren"}, {"to": "7010", "prefix": " Interactions\n                  \n                  Because ", "from": "7003", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " is primarily metabolized by aldehyde oxidase, and to a less"}, {"to": "7157", "prefix": " inhibitors of these enzymes might be expected to decrease ", "from": "7150", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": "'s clearance and inducers of these enzymes might be expected"}, {"to": "7253", "prefix": "these enzymes might be expected to increase its clearance. ", "from": "7246", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " has been shown to have minimal effects on the kinetics of w"}, {"to": "7452", "prefix": "ramine, thioridazine, and digoxin. However, the effects of ", "from": "7445", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " on inhibition of enzymes involved in the metabolism of othe"}, {"to": "7748", "prefix": "ntrolled Trials Supporting Effectiveness\n                  ", "from": "7741", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "8640", "prefix": "parallel-group trial comparing the effects of two doses of ", "from": "8633", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "8680", "prefix": " with placebo. ", "from": "8673", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg, but not 5 mg, was superior to placebo in decreasing "}, {"to": "9127", "prefix": " and two of 4 weeks duration, that compared the effects of ", "from": "9120", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " at doses of 5 mg "}, {"to": "9255", "prefix": ". ", "from": "9248", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg and 20 mg were consistently superior to placebo for T"}, {"to": "9582", "prefix": "ve than were the 10-mg and 20-mg doses. Sleep latency with ", "from": "9575", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg and 20 mg was on the order of 10-20 minutes "}, {"to": "9940", "prefix": "ghts. Overall, these studies demonstrated a superiority of ", "from": "9933", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg and 20 mg over placebo in reducing LPS on the first 2"}, {"to": "10229", "prefix": " placebo group, and thus, a significant difference between ", "from": "10222", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " and placebo was not seen beyond 2 nights. In a 35-night stu"}, {"to": "10301", "prefix": "placebo was not seen beyond 2 nights. In a 35-night study, ", "from": "10294", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 10 mg was significantly more effective than placebo in redu"}, {"to": "10636", "prefix": "llel-group outpatient studies that compared the effects of ", "from": "10629", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " 5 mg and 10 mg with placebo on a subjective measure of time"}, {"to": "10727", "prefix": ". ", "from": "10720", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " at both doses was superior to placebo on TSO, generally for"}, {"to": "11146", "prefix": "ving doses of 5 mg and 10 mg. Both 5-mg and 10-mg doses of ", "from": "11139", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " were superior to placebo in reducing latency to persistent "}, {"to": "11689", "prefix": "g the exposure of normal subjects to single fixed doses of ", "from": "11682", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "11933", "prefix": " short-term memory at 1 hour, the time of peak exposure to ", "from": "11926", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", for both doses, with a tendency for the effect to be great"}, {"to": "12056", "prefix": "reater after 20 mg. Consistent with the rapid clearance of ", "from": "12049", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", memory impairment was no longer present as early as 2 hour"}, {"to": "12319", "prefix": "premarketing clinical trials revealed a difference between ", "from": "12312", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " and placebo in the risk of next-day amnesia "}, {"to": "12597", "prefix": "g the exposure of normal subjects to single fixed doses of ", "from": "12590", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "12929", "prefix": "ychomotor function at 1 hour, the time of peak exposure to ", "from": "12922", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", for both doses. Consistent with the rapid clearance of zal"}, {"to": "12994", "prefix": "on, for both doses. Consistent with the rapid clearance of ", "from": "12987", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": ", impairment of psychomotor function was no longer present a"}, {"to": "13267", "prefix": "eting clinical trials did not suggest a difference between ", "from": "13260", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " and placebo in the risk of next-day somnolence "}, {"to": "14094", "prefix": "e of increased signs of daytime anxiety.\n                  ", "from": "14087", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " has a short half-life and no active metabolites. At the pri"}, {"to": "14328", "prefix": " showed that wakefulness was not significantly longer with ", "from": "14321", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " than with placebo during the last quarter of the night. No "}, {"to": "14474", "prefix": "ns of daytime anxiety was observed in clinical trials with ", "from": "14467", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": ". In two sleep laboratory studies involving 14- and 28-night"}, {"to": "14554", "prefix": "p laboratory studies involving 14- and 28-nightly doses of ", "from": "14547", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " "}, {"to": "14884", "prefix": "ported daytime anxiety, no difference was observed between ", "from": "14877", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " and placebo.\n                  Rebound insomnia, defined as"}, {"to": "15230", "prefix": "g hypnotics. Rebound insomnia following discontinuation of ", "from": "15223", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " relative to baseline was examined at both nights 1 and 2 fo"}, {"to": "15701", "prefix": "on the first night after discontinuation of treatment with ", "from": "15694", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": ". At 5 mg and 10 mg, there was no objective and minimal subj"}, {"to": "15864", "prefix": "on the first night after discontinuation of treatment with ", "from": "15857", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": ". At all doses, the rebound effect appeared to resolve by th"}, {"to": "16296", "prefix": "nsomnia, and appeared to resolve by the second night after ", "from": "16289", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "zaleplon", "suffix": " discontinuation.\n                  Other Withdrawal-Emergen"}, {"to": "16861", "prefix": "emergence of 3 or more new symptoms after discontinuation. ", "from": "16854", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " was not distinguishable from placebo at doses of 5 mg, 10 m"}, {"to": "16966", "prefix": "at doses of 5 mg, 10 mg, or 20 mg on this measure, nor was ", "from": "16959", "name": "zaleplon", "fullId": "http://purl.bioontology.org/ontology/MESH/C085665", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Zaleplon", "suffix": " distinguishable from placebo on spontaneously reported with"}, {"to": "293", "prefix": "is a hypnotic agent with a chemical structure unrelated to ", "from": "279", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "benzodiazepines", "suffix": ", barbiturates, or other drugs with known hypnotic propertie"}, {"to": "416", "prefix": " properties, it interacts with the gamma-aminobutyric acid-", "from": "403", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "benzodiazepine", "suffix": " "}, {"to": "623", "prefix": " responsible for some of the pharmacological properties of ", "from": "609", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "benzodiazepines", "suffix": ", which include sedative, anxiolytic, muscle relaxant, and a"}, {"to": "16605", "prefix": "nd in open-label studies of 6- and 12-month durations. The ", "from": "16592", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "Benzodiazepine", "suffix": " Withdrawal Symptom Questionnaire was used in several of the"}, {"to": "401", "prefix": "rugs with known hypnotic properties, it interacts with the ", "from": "379", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "gamma-aminobutyric acid", "suffix": "-benzodiazepine "}, {"to": "422", "prefix": "", "from": "419", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "GABA", "suffix": "-BZ"}, {"to": "475", "prefix": " receptor complex. Subunit modulation of the ", "from": "472", "name": "gamma-Aminobutyric Acid", "fullId": "http://purl.bioontology.org/ontology/MESH/D005680", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "GABA", "suffix": "-BZ receptor chloride channel macromolecular complex is hypo"}, {"to": "7320", "prefix": " has been shown to have minimal effects on the kinetics of ", "from": "7313", "name": "Warfarin", "fullId": "http://purl.bioontology.org/ontology/MESH/D014859", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "warfarin", "suffix": " "}, {"to": "7354", "prefix": ", ", "from": "7345", "name": "Imipramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5691", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "imipramine", "suffix": ", ethanol, ibuprofen, diphenhydramine, thioridazine, and dig"}, {"to": "7363", "prefix": ", imipramine, ", "from": "7357", "name": "Ethanol", "fullId": "http://purl.bioontology.org/ontology/RXNORM/448", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ethanol", "suffix": ", ibuprofen, diphenhydramine, thioridazine, and digoxin. How"}, {"to": "7374", "prefix": ", imipramine, ethanol, ", "from": "7366", "name": "Ibuprofen", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5640", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "ibuprofen", "suffix": ", diphenhydramine, thioridazine, and digoxin. However, the e"}, {"to": "7391", "prefix": ", imipramine, ethanol, ibuprofen, ", "from": "7377", "name": "Diphenhydramine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3498", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "diphenhydramine", "suffix": ", thioridazine, and digoxin. However, the effects of zaleplo"}, {"to": "7405", "prefix": ", imipramine, ethanol, ibuprofen, diphenhydramine, ", "from": "7394", "name": "Thioridazine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/10502", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "thioridazine", "suffix": ", and digoxin. However, the effects of zaleplon on inhibitio"}, {"to": "7418", "prefix": "ne, ethanol, ibuprofen, diphenhydramine, thioridazine, and ", "from": "7412", "name": "Digoxin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/3407", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "digoxin", "suffix": ". However, the effects of zaleplon on inhibition of enzymes "}, {"to": "12111", "prefix": "zaleplon, memory impairment was no longer present as early ", "from": "12108", "name": "Aligeron", "fullId": "http://purl.bioontology.org/ontology/MESH/C021591", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "as 2", "suffix": " hours post dosing in one study, and in none of the studies "}, {"to": "13066", "prefix": "ent of psychomotor function was no longer present as early ", "from": "13063", "name": "Aligeron", "fullId": "http://purl.bioontology.org/ontology/MESH/C021591", "setId": "2f44db39-e1d9-451e-ba31-e4b10366a430", "exact": "as 2", "suffix": " hours post dosing in one study, and in none of the studies "}, {"to": "224", "prefix": "reful adjustment of dosage are required when administering ", "from": "214", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " concomitantly with anticholinergic or sympathomimetic drugs"}, {"to": "411", "prefix": "ects.\n                        Concurrent administration of ", "from": "401", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " with electroshock therapy should be avoided because of the "}, {"to": "586", "prefix": "            Caution should be exercised when administering ", "from": "576", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " to hyperthyroid patients or those on thyroid medication bec"}, {"to": "734", "prefix": "ility of enhanced potential for cardiovascular toxicity of ", "from": "724", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": ".\n                        Maprotiline should be used with ca"}, {"to": "771", "prefix": "ovascular toxicity of maprotiline.\n                        ", "from": "761", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "Maprotiline", "suffix": " should be used with caution in patients receiving guanethid"}, {"to": "992", "prefix": "                The risk of seizures may be increased when ", "from": "982", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " is taken concomitantly with phenothiazines or when the dosa"}, {"to": "1126", "prefix": "f benzodiazepines is rapidly tapered in patients receiving ", "from": "1116", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": ".\n                        Because of the pharmacologic simil"}, {"to": "1294", "prefix": "the tricyclic antidepressants, the plasma concentration of ", "from": "1284", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/RXNORM/6646", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline", "suffix": " may be increased when the drug is given concomitantly with "}, {"to": "1220", "prefix": "                Because of the pharmacologic similarity of ", "from": "1196", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D008376", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline hydrochloride", "suffix": " to the tricyclic antidepressants, the plasma concentration "}, {"to": "1618", "prefix": "ith tricyclic antidepressants. Adjustment of the dosage of ", "from": "1594", "name": "Maprotiline", "fullId": "http://purl.bioontology.org/ontology/MESH/D008376", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "maprotiline hydrochloride", "suffix": " may therefore be necessary in such cases.\n                 "}, {"to": "332", "prefix": "mpathomimetic drugs because of the possibility of additive ", "from": "325", "name": "Atropine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/1223", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "atropine", "suffix": " like effects.\n                        Concurrent administra"}, {"to": "834", "prefix": "rotiline should be used with caution in patients receiving ", "from": "823", "name": "Guanethidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/5036", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "guanethidine", "suffix": " or similar agents since it may block the pharmacologic effe"}, {"to": "1073", "prefix": "en concomitantly with phenothiazines or when the dosage of ", "from": "1059", "name": "Benzodiazepines", "fullId": "http://purl.bioontology.org/ontology/MESH/D001569", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "benzodiazepines", "suffix": " is rapidly tapered in patients receiving maprotiline.\n     "}, {"to": "1397", "prefix": "e.g., ", "from": "1388", "name": "Cimetidine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/2541", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "cimetidine", "suffix": ", fluoxetine"}, {"to": "1409", "prefix": "e.g., cimetidine, ", "from": "1400", "name": "Fluoxetine", "fullId": "http://purl.bioontology.org/ontology/RXNORM/4493", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "fluoxetine", "suffix": ""}, {"to": "1514", "prefix": "e.g., barbiturates, ", "from": "1506", "name": "Phenytoin", "fullId": "http://purl.bioontology.org/ontology/RXNORM/8183", "setId": "c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87", "exact": "phenytoin", "suffix": ""}]